Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
NANT Neoadjuvant TNBC Vaccine
- Development stage
- Discontinued
- Lead developer
- ImmunityBio
- Modality
- Small Molecules, CAR-NK Cells → Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies, Monoclonal Antibodies → Antibody-Based Therapeutics, Lymphokine-Activated Killer Cells → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies, Cytokines & Interferons → Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Administration
- Intravenous, Subcutaneous, Intramuscular, Oral
01
Overview
The NANT Neoadjuvant TNBC Vaccine is an investigational, molecularly informed multi-agent neoadjuvant immunotherapy regimen developed by ImmunityBio for previously untreated stage II or III triple-negative breast cancer. In the withdrawn Phase 2 QUILT-3.057 study, the regimen combined metronomic cytotoxic chemotherapy, antigen-directed yeast and adenoviral-vector therapeutic cancer vaccines, the IL-15 superagonist ALT-803, haNK allogeneic natural killer cells, and the anti-PD-L1 antibody avelumab. Its intended strategy was to promote immunogenic tumor-cell death, induce antigen-specific T-cell responses, activate NK and T cells, and relieve PD-L1-mediated immune suppression before surgery. ([ctv.veeva.com](https://ctv.veeva.com/study/quilt-3057-nant-neoadjuvant-triple-negative-breast-cancer-tnbc-vaccine))
- Other names
- NANT Neoadjuvant TNBC VaccineNANT Neoadjuvant Triple-Negative Breast Cancer Vaccine
02
Targets
MHC I (MHC class I})IL-15R (Interleukin 15 receptor alpha/interleukin 15 complex)TUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on NANT Neoadjuvant TNBC Vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on NANT Neoadjuvant TNBC Vaccine.